Fig 2: Gal-1 is highly expressed in the tumor microenvironment and associated with decreased survival(A) RNA sequencing data for LGALS1 (galectin-1), LGALS3 (galectin-3), and LGALS8 (galectin-8) in a number of human tumor samples (red boxes) and the corresponding normal samples (blue boxes).(B) Immunofluorescent staining of gal-1, gal-3, and gal-8 in oral squamous cell carcinomas and normal human oral epithelia.(C) Immunohistochemistry of Gal-1 of pancreatic adenocarcinomas and head and neck squamous cell carcinoma. Specimens from three different patients are shown for each cancer. Images were extracted from the Human Proteome Atlas (https://www.proteinatlas.org). In all images Gal-1 is expressed predominantly in the stroma, although expression in the epithelial compartment is also observed in some cancers; a feature that is especially prominent in one of the cases of kidney adenocarcinomas.(D) Overall survival analysis in head and neck cancer and pancreatic cancer. The survival analysis was done at GEPIA with default settings (http://gepia2.cancer-pku.cn). Data in (A and D) were obtained from the online database GEPIA.16 CHOL, cholangial carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; PAAD, pancreatic adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THYM, thymoma.